Clara Mazagatos, Jacobo Mendioroz, Mercedes Belén Rumayor, Virtudes Gallardo García, Virginia Álvarez Río, Ana Delia Cebollada Gracia, Noa Batalla Rebollo, María Isabel Barranco Boada, Olaia Pérez-Martínez, Ana Sofía Lameiras Azevedo, Nieves López González-Coviella, Daniel Castrillejo, Ana Fernández Ibáñez, Jaume Giménez Duran, Cristina Ramírez Córcoles, Violeta Ramos Marín, Amparo Larrauri, Susana Monge, The SARI Sentinel Surveillance RSV Study Group
{"title":"2023年第40周至2024年第8周,西班牙,Nirsevimab对需住院治疗的1岁以下儿童呼吸道合胞病毒感染发生率的影响估计。","authors":"Clara Mazagatos, Jacobo Mendioroz, Mercedes Belén Rumayor, Virtudes Gallardo García, Virginia Álvarez Río, Ana Delia Cebollada Gracia, Noa Batalla Rebollo, María Isabel Barranco Boada, Olaia Pérez-Martínez, Ana Sofía Lameiras Azevedo, Nieves López González-Coviella, Daniel Castrillejo, Ana Fernández Ibáñez, Jaume Giménez Duran, Cristina Ramírez Córcoles, Violeta Ramos Marín, Amparo Larrauri, Susana Monge, The SARI Sentinel Surveillance RSV Study Group","doi":"10.1111/irv.13294","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Data from the sentinel surveillance system of severe acute respiratory infections in Spain were used to estimate the impact of administration of nirsevimab to children born from 1 April 2023 onwards.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Estimated RSV hospitalisations in < 1-year-olds during weeks 40, 2023, to 8, 2024, were compared to the number that would be expected after accounting for the background change in RSV circulation in the 2023/24 season, compared to 2022/23.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>We estimated 9364–9875 RSV hospitalisations less than expected, corresponding to a 74%–75% reduction.</p>\n </section>\n </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"18 5","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.13294","citationCount":"0","resultStr":"{\"title\":\"Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain\",\"authors\":\"Clara Mazagatos, Jacobo Mendioroz, Mercedes Belén Rumayor, Virtudes Gallardo García, Virginia Álvarez Río, Ana Delia Cebollada Gracia, Noa Batalla Rebollo, María Isabel Barranco Boada, Olaia Pérez-Martínez, Ana Sofía Lameiras Azevedo, Nieves López González-Coviella, Daniel Castrillejo, Ana Fernández Ibáñez, Jaume Giménez Duran, Cristina Ramírez Córcoles, Violeta Ramos Marín, Amparo Larrauri, Susana Monge, The SARI Sentinel Surveillance RSV Study Group\",\"doi\":\"10.1111/irv.13294\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Data from the sentinel surveillance system of severe acute respiratory infections in Spain were used to estimate the impact of administration of nirsevimab to children born from 1 April 2023 onwards.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Estimated RSV hospitalisations in < 1-year-olds during weeks 40, 2023, to 8, 2024, were compared to the number that would be expected after accounting for the background change in RSV circulation in the 2023/24 season, compared to 2022/23.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>We estimated 9364–9875 RSV hospitalisations less than expected, corresponding to a 74%–75% reduction.</p>\\n </section>\\n </div>\",\"PeriodicalId\":13544,\"journal\":{\"name\":\"Influenza and Other Respiratory Viruses\",\"volume\":\"18 5\",\"pages\":\"\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-05-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.13294\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Influenza and Other Respiratory Viruses\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/irv.13294\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.13294","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain
Background
Data from the sentinel surveillance system of severe acute respiratory infections in Spain were used to estimate the impact of administration of nirsevimab to children born from 1 April 2023 onwards.
Methods
Estimated RSV hospitalisations in < 1-year-olds during weeks 40, 2023, to 8, 2024, were compared to the number that would be expected after accounting for the background change in RSV circulation in the 2023/24 season, compared to 2022/23.
Results
We estimated 9364–9875 RSV hospitalisations less than expected, corresponding to a 74%–75% reduction.
期刊介绍:
Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases.
Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.